ResearchMoz added Latest Research Report titled " Peripheral Artery Disease - China Drug Forecast and Market Analysis to 2024 " to it's Large Report database.
Peripheral Artery Disease - China Drug Forecast and Market Analysis to 2024
Summary
In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.s Zontivity (vorapaxar), AstraZenecas Brilinta (ticagrelor), and Bayer and Janssens (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=816334
In 2014, the PAD therapeutics market in China was worth approximately $93.7m. Generic anticoagulant drugs, primarily warfarin, will suffer a negative CAGR of approximately 10.15% as Xarelto and generic rivaroxaban begin to encroach on warfarins stake in the PAD market.
Scope
- Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product PADcription, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting China PAD market.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Classification and Staging Systems 15
3.3 Symptoms and Clinical Presentation 17
3.4 Prognosis 21
3.5 Quality of Life 25
4 Disease Management 27
4.1 Diagnosis and Treatment Overview 27
4.1.1 Diagnosis 27
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 31
4.2 Urban China 32
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
Peripheral Artery Disease - China Drug Forecast and Market Analysis to 2024
Summary
In the 2014 base year, the global PAD market was worth approximately $543.4m, including both branded and generic drugs. By 2024, GlobalData expects that the global PAD market will experience significant expansion, with a Compound Annual Growth Rate (CAGR) of approximately 4.15%, equating to around $816.3m. The dramatic increase in the value of the overall global PAD therapeutics market will be partly attributable to the launch of several PAD drugs currently in late-stage pipeline development, which GlobalData believes have extraordinary potential. These include the novel antithrombotic pharmacological agents, Merck & Co.s Zontivity (vorapaxar), AstraZenecas Brilinta (ticagrelor), and Bayer and Janssens (a subsidiary of Johnson & Johnson) Xarelto (rivaroxaban), which have the capacity to reform the antiplatelet and anticoagulatory PAD treatment landscape.
Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=816334
In 2014, the PAD therapeutics market in China was worth approximately $93.7m. Generic anticoagulant drugs, primarily warfarin, will suffer a negative CAGR of approximately 10.15% as Xarelto and generic rivaroxaban begin to encroach on warfarins stake in the PAD market.
Scope
- Overview of PAD including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product PADcription, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2014-2024.
- Analysis of the impact of key events as well the drivers and restraints affecting China PAD market.
Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html
Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Classification and Staging Systems 15
3.3 Symptoms and Clinical Presentation 17
3.4 Prognosis 21
3.5 Quality of Life 25
4 Disease Management 27
4.1 Diagnosis and Treatment Overview 27
4.1.1 Diagnosis 27
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 31
4.2 Urban China 32
About ResearchMoz
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Contact Us:
Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG
No comments:
Post a Comment